ASH 2023 | First-line venetoclax plus HMA vs intensive chemotherapy in older adults with IDH-mutated AML

Keri Maher, DO, VCU Health, Richmond, VA, discusses a retrospective analysis of data from 50 patients (≥60 years of age) with IDH-mutated acute myeloid leukemia (AML) who received conventional intensive chemotherapy (IC) or a treatment regimen of venetoclax plus a hypomethylating agent (HMA; decitabine or azacitidine). The study elucidated that, despite various differences in patient factors, there was no significant difference in overall survival (OS) between the two treatment modalities. HMA monotherapy was used as a comparison arm, and both IC and venetoclax plus HMA resulted in significantly prolonged survival compared to HMA alone. These findings will require confirmation through prospective trial designs in molecularly selected cohorts. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.